ALPORT SYNDROME
Clinical trials for ALPORT SYNDROME explained in plain language.
Never miss a new study
Get alerted when new ALPORT SYNDROME trials appear
Sign up with your email to follow new studies for ALPORT SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug aims to fix faulty kidney protein in rare genetic disease
Disease control CompletedThis small, early-stage study tested whether daily injections of an experimental drug called ELX-02 are safe and can improve kidney health in adults with a specific genetic form of Alport Syndrome. The drug is designed to help the body produce a crucial protein that is missing du…
Matched conditions: ALPORT SYNDROME
Phase: PHASE2 • Sponsor: Eloxx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for Hard-to-Treat kidney diseases in early trial
Disease control CompletedThis study tested an experimental drug called R3R01 for people with two serious kidney diseases: Alport Syndrome and Focal Segmental Glomerulosclerosis (FSGS). The main goal was to see if the drug was safe and if it could reduce high levels of protein in the urine, a key sign of …
Matched conditions: ALPORT SYNDROME
Phase: PHASE2 • Sponsor: River 3 Renal Corp. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New drug tested to slow kidney damage in rare genetic disease
Disease control CompletedThis study tested whether a drug called vonafexor is safe and can help protect kidney function in people with Alport syndrome, a genetic condition that damages the kidneys over time. It involved 26 patients who were at risk of their disease getting worse. Participants took the dr…
Matched conditions: ALPORT SYNDROME
Phase: PHASE2 • Sponsor: Enyo Pharma • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
New drug tested to slow kidney damage in rare genetic disease
Disease control CompletedThis study tested whether adding an experimental drug called setanaxib to standard care could help protect kidney function in people with Alport syndrome, a rare genetic condition that damages the kidneys. Twenty patients aged 12-50 received either setanaxib or a placebo pill for…
Matched conditions: ALPORT SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: Calliditas Therapeutics AB • Aim: Disease control
Last updated Mar 12, 2026 13:50 UTC
-
Patients unite to map a rare kidney disease
Knowledge-focused CompletedThis study created a central registry of 655 patients and families affected by Alport syndrome, a rare genetic kidney disease. The goal was to collect information to better understand the disease and to help plan future research into potential treatments. It did not test any trea…
Matched conditions: ALPORT SYNDROME
Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:27 UTC